ATCOR develops and markets technologies that help clinicians identify, diagnose, and treat patients with confidence.
ATCOR is the world leader in medical devices for measuring arterial stiffness and central blood pressure waveforms based on its unique FDA-cleared and patented SphygmoCor® technology. More than 4,500 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company’s technology has been featured in over 1,600 peer-reviewed studies published in leading medical journals and thousands of citations.
Under the ATCOR.X brand, the company also develops and licenses its Arty™ platform consisting of physiological and health analytics for wearable devices. The company's digital platform, ArtyNet™, is a connected SaaS ecosystem providing physicians with a complete telehealth solution for remotely managing patients' health (2021 launch).
ATCOR's manufacturing and R&D operations are located in Sydney. The American subsidiary, ATCOR Medical Inc., is headquartered in Naperville, Illinois. Executive offices are located in Newport Beach, California and business development for Asian markets is located in Shanghai. ATCOR is a 100% owned subsidiary of CardieX, Limited, an Australian publicly listed company (ASX:CDX).